Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma
We demonstrated that complement C3a interacts with Sirt1 in osteoclasts to participate in the pathogenesis of MBD. Complement C3a promotes osteoclast formation by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with MM, which is reduced by treatment with a Sirt1 activator. The application of a Sirt1 activator can reduce the formation of osteoclasts and reduce the severity of bone diseases in vivo and may be useful for the treatment of MBD. This study identified novel potential therapeutic targets and strategies for patients with MBD.
Authors
- Zhaoyun Liu (ORCID: https://orcid.org/0000-0002-2730-1562)
- Fengping Peng (ORCID: https://orcid.org/0000-0002-1761-1399)
- Panpan Cao
- Hui Liu (ORCID: https://orcid.org/0000-0002-7206-8747)
- Lijuan Li (ORCID: https://orcid.org/0000-0001-5984-1603)
- Rong Fu (ORCID: https://orcid.org/0000-0002-9928-9224)
- Yunhe Zhang (ORCID: https://orcid.org/0000-0001-8483-6486)
- Xiaohan Liu (ORCID: https://orcid.org/0000-0002-1154-8122)
- Kai Ding (ORCID: https://orcid.org/0000-0003-0160-4650)
- Fengjuan Jiang (ORCID: https://orcid.org/0000-0002-3994-0513)
Institutions
- Tianjin University of Sport (CN)
- Tianjin Normal University (CN)
- Tianjin University (CN)
- Tianjin Medical University General Hospital (CN)
- Tianjin Special Equipment Supervision and Inspection Technology Research Institute (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-16
- DOI
- https://doi.org/10.1186/s12967-025-06319-3
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- China Postdoctoral Science Foundation
- Natural Science Foundation of Tianjin City
- Tianjin Science and Technology Program